In a heterogeneous meta-analysis of 23 NSCLC chemotherapy-based studies, 2631 patients with KRAS mutations and an adenocarcinoma subtype had poor prognoses, with a statistically worse overall survival than patients without KRAS mutations [7]. This evidence concerns the gene KRAS and adenocarcinoma.